A Phase 2 Study of Abemaciclib for Patients With Retinoblastoma-Positive, Triple Negative Metastatic Breast Cancer
Latest Information Update: 15 Feb 2024
At a glance
- Drugs Abemaciclib (Primary)
- Indications Advanced breast cancer; Triple negative breast cancer
- Focus Therapeutic Use
- 26 Aug 2022 Status changed from active, no longer recruiting to discontinued.
- 12 Oct 2021 Status changed from recruiting to active, no longer recruiting.
- 12 Aug 2020 Planned End Date changed from 30 Nov 2024 to 30 Nov 2025.